Skip to main content
Premium Trial:

Request an Annual Quote

Personal Genome Diagnostics, Blueprint Medicines to ID Novel Drug Targets in Cancer

NEW YORK (GenomeWeb News) – Cancer genome analysis firm Personal Genome Diagnostics said today that it will collaborate with Blueprint Medicines to search for novel kinase targets for cancer drugs.

Personal Genome Diagnostics will use exome sequencing as well as its own proprietary digital karyotyping technology, which it licensed from Johns Hopkins, to analyze copy number changes in cancer genomes.

Blueprint Medicines has built a proprietary genomics platform to identify novel targets and potential combination therapies and has a broad library of novel kinase inhibitor compounds.

The firms plan to analyze a "series of cancer subtypes that have not been examined before," with the goal of "identifying key genomic drivers of cancer and leveraging these insights to develop the next generation of highly selective and tailored kinase inhibitors," Christoph Lengauer, Blueprint's chief scientific officer, said in a statement.

PGDx was founded in 2010 by researchers from Johns Hopkins University. Out of its CLIA-certified facility in Baltimore, it provides patient-specific tumor genome analysis, including exome sequencing, to identify genomic alterations and link them to the underlying cancer biology.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.